glp-1 news oct 21 2025 ISPOR 2025: Exploring reasons for discontinuation What's next for GLP-1 innovation:
Description
JAMA network open, 5(12), e2244912
Recent prescribing patterns underscore this trend
#MASH #LiverHealth #GLP1 #Semaglutide #MedicalResearch #CellMetabolism #Hepatology #Innovation | 31 comments on LinkedIn
Diabetesmellitus (DM) is a group of metabolic diseases classified by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both
Leave-one-out sensitivity analyses confirmed the direction and magnitude of the AUD finding but highlighted the limited evidence base for hospitalization
